Crossmark

A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer

Crossref DOI link: https://doi.org/10.1007/s10549-015-3646-2

Published Online: 2015-12-07

Published Print: 2016-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jacobs, C.

Kuchuk, I.

Bouganim, N.

Smith, S.

Mazzarello, S.

Vandermeer, L.

Dranitsaris, G.

Dent, S.

Gertler, S.

Verma, S.

Song, X.

Simos, S.

Cella, D.

Clemons, M.
Funding

Funding for this research was provided by:

Canadian Breast Cancer Foundation
License Information

Text and Data Mining valid from 2015-12-07

Document is current

Any future updates will be listed below